Building a National Strategy for Drugs for Rare Diseases: What We Heard from Canadians

Canadians with rare diseases want access to drugs that could help manage and treat their conditions. Those drugs, however, can be extremely expensive. Advisory Council on the Implementation of National Pharmacare recommended creating a national strategy for providing fair, consistent and evidence-based access for patients to these specialized drugs. In response, the Government of Canada made a commitment to work with provinces, territories and other partners to create a national strategy for drugs for rare diseases.

Data and Resources

Additional Info

Field Value
Source
Version None
Author None
Author Email None
Maintainer None
Maintainer Email None
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Élaboration d'une stratégie nationale sur les médicaments pour le traitement des maladies rares: ce que nous avons entendu des Canadiens
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2021-06-18 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["stratégie nationale pour les médicaments", "maladies rares", "médicaments spécialisés", "médicaments pour les maladies rares", "ce que nous avons entendu", "accès aux médicaments", "Conseil consultatif", "National Pharmacare", "accès équitable", "accès cohérent", "accès fondé sur des données probantes pour les patients"], "en": ["national strategy for drugs", "rare diseases", "specialized drugs", "drugs for rare diseases", "what we heard", "access to drugs", "Advisory Council", "National Pharmacare", "fair access", "consistent access", "evidence-based access for patients"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source